Table 3 Correlation of CLEC3B expression and prognosis in lung cancer with clinicopathological factors by Kaplan-Meier plotter
Clinicopathological characteristics | Overall survival (n = 1928) | Progression-free survival (n = 982) | ||||
|---|---|---|---|---|---|---|
N | HR (95% CI) | p-value | N | HR (95% CI) | p-value | |
Sex | ||||||
Female | 715 | 0.64 (0.5–0.81) | 0.00022 | 468 | 0.59 (0.44–0.80) | 0.00051 |
Male | 1100 | 0.69 (0.59–0.81) | 5.9e−06 | 514 | 0.62 (0.48–0.80) | 0.00026 |
Stage | ||||||
1 | 577 | 0.58 (0.44–0.76) | 5.85e−05 | 325 | 0.51 (0.33–0.81) | 0.0033 |
2 | 244 | 1.61 (1.06–2.45) | 0.024 | 130 | 0.40 (0.20–0.81) | 0.0089 |
3 | 70 | 1.49 (0.83–2.70) | 0.18 | 19 | na | na |
4 | 4 | na | na | 0 | na | na |
T stage | ||||||
1 | 437 | 0.64 (0.48–0.86) | 0.0024 | 177 | 0.49 (0.29–0.84) | 0.008 |
2 | 589 | 0.66 (0.52–0.83) | 0.00044 | 351 | 0.50 (0.34–0.74) | 4e−04 |
3 | 81 | 1.69 (1.03–2.78) | 0.037 | 21 | 0.65 (0.24–1.80) | 0.41 |
4 | 46 | 0.50 (0.26–0.96) | 0.033 | 7 | na | na |
N stage | ||||||
0 | 781 | 0.69 (0.56–0.86) | 0.00066 | 374 | 0.59 (0.43–0.82) | 0.0013 |
1 | 252 | 0.67 (0.48–0.92) | 0.014 | 130 | 0.38 (0.21–0.67) | 0.00051 |
2 | 111 | 0.72 (0.45–1.14) | 0.15 | 51 | 0.50 (0.25–1.00) | 0.047 |
M stage | ||||||
0 | 681 | 0.61 (0.49–0.75) | 2.3e−06 | 195 | 0.56 (0.33–0.94) | 0.026 |
1 | 10 | na | na | 0 | na | na |
Grade | ||||||
I | 201 | 0.84 (0.58–1.21) | 0.35 | 140 | 0.68 (0.42–1.10) | 0.12 |
II | 310 | 0.63 (0.45–0.87) | 0.0052 | 165 | 0.48 (0.30–0.77) | 0.002 |
III | 77 | 0.47 (0.24–0.91) | 0.022 | 51 | 1.47 (0.64–3.35) | 0.36 |
Smoke | ||||||
Ever | 820 | 0.76 (0.62–0.93) | 0.0082 | 603 | 0.58 (0.44–0.75) | 2.7e−05 |
Never | 205 | 0.41 (0.23–0.72) | 0.0013 | 193 | 0.48 (0.29–0.79) | 0.0032 |